Femara 2.5 - Novartis

Introduced in 1997 by Novartis under the name Femara, letrozole became one of the most potent third-generation aromatase inhibitors, quickly gaining FDA approval for its efficacy in treating breast cancer in postmenopausal women. By preventing the enzyme aromatase from converting androgens to estrogen, letrozole achieves substantial estrogen suppression. Given its potency, letrozole found utility beyond medicine, reducing estrogenic side effects like water retention and gynecomastia for steroid users. However, long-term use may impact bone density, making cyclic use favorable​.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Femara 2.5 by Novartis, consult with your doctor or healthcare professional.